
On the 23rd, the specialized pharmaceutical manufacturing company Jeroncellvein announced that the '2026 2nd PDRN Symposium', sponsored by the PDRN Immunoregenerative Dentistry Research Association (PIRDMA), was successfully concluded.
This symposium, attended by approximately 300 experts, featured a wide range of discussions, from the scientific mechanisms of polydeoxyribonucleotides (PDRN) to clinical application cases and future industrial expansion strategies.
Speakers included Kim Deok-gyu, CEO of Geroncellbein, Yoon Jong-il, Vice President of PDRN Immunoregenerative Dentistry Research Group (Director of Yonsei Dental Clinic), Park Won-seo, Professor at Yonsei University Dental Hospital, Koo Ki-tae, Professor at Seoul National University Dental Hospital, Kwon Yong-dae, Professor at Kyunghee University Dental Hospital, Koo Jeong-gui, Professor at Bundang Seoul National University Hospital, Kim Young-jun, Professor at Yeongsan University, Kim Yong-jin, Director of Yesmir Dental Clinic, Kim Hyeong-jun, Director of OFP Oral Medicine and Dentistry, and Jang Hyeon-dong, Director of Hyeon Hospital (President of the Korean Association of Oral Surgeons).
Kim Jae-hong, Chairman of the PDRN Immunoregenerative Dentistry Research Association, expressed his gratitude to the top speakers in the PDRN field in Korea and emphasized the potential based on various basic research and clinical results using 'Celvein Injection' by Geroncellvein, which is widely known as a PDRN specialized drug in the dental clinical field.
In particular, the symposium focused on introducing the potential applications of Geroncellbein's specialized pharmaceutical product 'Celbein Injection' in various wellness and medical fields, including not only dentistry and osteoimmunology, but also skin regeneration and beauty, along with its physiological properties such as tissue regeneration promotion and anti-inflammatory action.
The company explained that attendees shared the latest research trends and practical application cases and showed great interest in the role that PDRN-based solutions will play in the next-generation bio market.
Yoon Jong-il, Vice President of PDRN Immunoregenerative Dentistry Research Group and Director of Yeon Dental Clinic, said, “The fundamental treatment of our body begins with immunity,” and “The core is to activate the ‘Natural Healing Process’ that restores damaged tissue. PDRN is a DNA fragment extracted from salmon testis that helps control inflammation and regenerate tissue at the same time.”
Director Yoon explained the relationship between PDRN and the clinical recovery process, focusing on its mechanism of alleviating excessive inflammatory responses and creating a tissue regeneration environment, and suggested the possibility of expanding combination treatment strategies due to its relatively low burden of drug interactions.
Kim Deok-gyu, CEO of Geron Cellbein, said, “This symposium, now in its second year, was an opportunity to further concretize the scientific basis and clinical value of PDRN,” and “We confirmed that the scope of application of Geron Cellbein’s ‘Celbein Injection’ is continuously expanding through the experiences and research results of medical professionals in various fields.”
He continued, “We will continue to promote the standardization and advancement of PDRN-based treatments through continuous research and development and academic exchanges, and provide solutions that are of practical help in the medical field.”
- See more related articles
You must be logged in to post a comment.